Micron develops pharmaceutical products, based on its proprietary microneedle patch technology, that are designed to provide enhanced vaccines and proprietary drugs efficacy, superior patient compliance, and simplified administration, distribution, and storage logistics.

The benefits of Micron’s microneedle patch technology stem from its proprietary design and manufacturing which allow for:

  • Skin-based targeting and delivery of actives

  • Painless administration and elimination of needle phobia

  • Customizable delivery profile based on indication

  • Ease of use (no applicator required) allowing administration by minimally-trained personnel or self-administration

  • Thermostability allowing reduction or elimination of the cold chain for transportation and storage

  • Simplified logistics (transportation and storage) due to the small size and thermostability of the microneedle patch

  • No sharps waste

Micron develops pharmaceutical products, based on its microneedle patch technology, that are designed to provide enhanced protective (vaccine) and therapeutic (drugs) effects, superior patient compliance, and simplified administration, distribution, and storage logistics.

News

Phase 1 clinical trial shows safety and immunogenicity of microneedle patch for flu vaccination for the first time

(GLOBE NEWSWIRE) — Using microneedle patch technology under development at Micron Biomedical, Inc. (Micron), a Phase 1 clinical trial showed that vaccination by microneedle patch was as safe and at least as immunogenic as vaccination with standard needle and syringe. The trial was carried out by the Georgia Institute of Technology (Georgia Tech) and the…

Micron to collaborate with Georgia Tech and CDC on measles-rubella project funded by UNICEF

ATLANTA, June 19, 2017 – UNICEF awards funding to support to work of Micron Biomedical, Inc. to develop cGMP manufacturing for a measles-rubella (MR) vaccine microneedle patch, to design and support pre-clinical studies, and to develop the regulatory strategy, including IND preparation, to support a future Phase 1/2a clinical trial and, ultimately, to obtain licensure…

Micron invited to participate in the BIO 2017 conference Innovation Zone

ATLANTA, April 12, 2017 – Micron Biomedical, Inc. was selected by NIH to participate in the BIO 2017 conference in San Diego, CA, June 19-22, 2017 and to exhibit in the Innovation Zone, an exhibit space dedicated to showcasing a small number of NIH SBIR/STTR awardees.  Micron was also selected to give a presentation on…